Objectives. To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and CCNU (C) for patients with locally advanced, squamous-cell carcinoma of the vulva (not amenable to resection by standard radical vulvectomy) or recurrent disease (after incomplete resection). Tumor resectability was reassessed in patients who had responded to chemotherapy. Methods. The regimen consisted of bleomycin 5 mg intramuscular (im) days 1–5, CCNU 40 mg per os (po) days 5–7, and methotrexate 15 mg po days 1 and 4 during the first week. During weeks 2–6 the patient was administered bleomycin 5 mg im days 1 and 4, and methotrexate 15 mg po on day 1 of the week. This 6-week cycle was repeated at 49-day intervals. Results. Twenty-five eligible patients with a median age of 66 years (range, 39–82 years) were entered in this phase II trial. Twelve patients had primary locally advanced disease, 13 patients had a locoregional recurrence, and all received up to three BMC cycles. Two complete and twelve partial responses were observed (response rate, 56%; 95% confidence limits, 35–76%). The BMC regimen was associated with major hematological side effects and mild signs of bleomycin-related pulmonary toxicity. At a median follow-up of 8 months, 3 patients were alive, 18 had died due to malignant disease, 2 had died due to toxicity, and 2 had died due to intercurrent disease and unknown cause. The median progression- free survival was 4.8 months and the median survival was 7.8 months. The 1-year survival was 32% (95% confidence limits, 13–51%). Conclusion. The present data confirm the therapeutic activity of the BMC regimen in locoregionally advanced or recurrent squamous- cell carcinoma of the vulva. Following neoadjuvant chemotherapy, the overall response rate was 56%. BMC is an outpatient treatment that may play a role in the palliative therapy of advanced or recurrent vulva cancer.
Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study / H.C. Wagenaar, N. Colombo, I. Vergote, G. Hoctin-Boes, G. Zanetta, S. Pecorelli, A.J. Lacave, Q. Van Hoesel, A. Cervantes, G. Bolis, M. Namer, C. Lhomme´, J.P. Guastalla, M.A. Nooij, A. Poveda, V. Scotto di Palumbo, J. B. Vermorken. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 81:3(2001 Jun), pp. 348-354. [10.1006/gyno.2001.6180]
Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study
G. Bolis;
2001
Abstract
Objectives. To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and CCNU (C) for patients with locally advanced, squamous-cell carcinoma of the vulva (not amenable to resection by standard radical vulvectomy) or recurrent disease (after incomplete resection). Tumor resectability was reassessed in patients who had responded to chemotherapy. Methods. The regimen consisted of bleomycin 5 mg intramuscular (im) days 1–5, CCNU 40 mg per os (po) days 5–7, and methotrexate 15 mg po days 1 and 4 during the first week. During weeks 2–6 the patient was administered bleomycin 5 mg im days 1 and 4, and methotrexate 15 mg po on day 1 of the week. This 6-week cycle was repeated at 49-day intervals. Results. Twenty-five eligible patients with a median age of 66 years (range, 39–82 years) were entered in this phase II trial. Twelve patients had primary locally advanced disease, 13 patients had a locoregional recurrence, and all received up to three BMC cycles. Two complete and twelve partial responses were observed (response rate, 56%; 95% confidence limits, 35–76%). The BMC regimen was associated with major hematological side effects and mild signs of bleomycin-related pulmonary toxicity. At a median follow-up of 8 months, 3 patients were alive, 18 had died due to malignant disease, 2 had died due to toxicity, and 2 had died due to intercurrent disease and unknown cause. The median progression- free survival was 4.8 months and the median survival was 7.8 months. The 1-year survival was 32% (95% confidence limits, 13–51%). Conclusion. The present data confirm the therapeutic activity of the BMC regimen in locoregionally advanced or recurrent squamous- cell carcinoma of the vulva. Following neoadjuvant chemotherapy, the overall response rate was 56%. BMC is an outpatient treatment that may play a role in the palliative therapy of advanced or recurrent vulva cancer.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
